Skip to main content
SpringerLink
Log in
Book cover

Cosmetic Dermatology pp 83–92Cite as

Botulinum Toxin

  • Chapter

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Carruthers A, Kiene K, Carruthers J (1996) Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol 34(5): 788–797

    Article  PubMed  CAS  Google Scholar 

  2. Tintner R, Jankovic J (2001) Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep 1(4): 337–345

    PubMed  CAS  Google Scholar 

  3. Smith ME, Ford CN (2000) Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 126(4): 533–535

    PubMed  CAS  Google Scholar 

  4. Siatkowski RM et al (1993) Serum antibody production to botulinum A toxin. Ophthalmology 100(12): 1861–1866

    PubMed  CAS  Google Scholar 

  5. Elan Pharmaceutical Inc (2000) Myobloc package insert

    Google Scholar 

  6. Guttman C (2002) Botulinum toxin type B option for wrinkles, sweating. Dermatology Times

    Google Scholar 

  7. Foster JA et al (1996) The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology 103(4): 618–622

    PubMed  CAS  Google Scholar 

  8. Scott AB, Rosenbaum A, Collins C (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12(12): 924–927

    PubMed  CAS  Google Scholar 

  9. Naumann M, Lowe NJ (2001) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised parallel group double blind placebo controlled trial. BMJ 323(7313): 596–599

    Article  PubMed  CAS  Google Scholar 

  10. Borodic GE, Cheney M, McKenna M (1992) Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg 90(6): 972–979

    PubMed  CAS  Google Scholar 

  11. Lowe NJ, Maxwell A, Harper H (1996) Botulinum A exotoxin for glabellar folds: a double-blind placebocontrolled study with an electromyographic injection technique. J Am Acad Dermatol 35(4): 569–572

    Article  PubMed  CAS  Google Scholar 

  12. Blitzer A et al (1997) The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 123(4): 389–392

    PubMed  CAS  Google Scholar 

  13. Fodor P, Nicanor GI, Hengst TC (1996) Endoscopically assisted plastic surgery. Mosby, St Louis

    Google Scholar 

  14. Allergan Pharmaceuticals (2002) Botox Cosmetic (botulinum toxin type A). Prescribing information

    Google Scholar 

  15. Carruthers A, Carruthers J (1994) Botulinum toxin used in the treatment of glabellar frown lines and other facial wrinkles. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin. Marcel Dekker, New York, pp 577–595

    Google Scholar 

  16. Dysport Cbotulinum type A toxin-haemagglutinin complex: patient information leaflet

    Google Scholar 

  17. Elan Pharmaceuticals (2004) Myobloc: Cosmetic use

    Google Scholar 

  18. Sadick NS, Faacs (2002) Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. Dermatol Surg 28(9): 817–821

    Article  PubMed  Google Scholar 

  19. Sadick NS (2003) Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2400 and 3000 U for the treatment of glabellar wrinkles. Dermatol Surg 29(5): 501–507

    Article  PubMed  Google Scholar 

  20. Spencer JM, Gordon M, Goldberg DJ (2002) Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis. J Cosmet Laser Ther 4(1): 19–23

    PubMed  Google Scholar 

  21. Ramirez AL, Reeck J, Maas CS (2002) Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 126(5): 459–467

    Article  PubMed  Google Scholar 

  22. Alster TSL, Lupton J R (2003) Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg 29(5): 516–518

    Article  PubMed  Google Scholar 

  23. Lowe NJ et al (2002) Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 4(1): 15–18

    PubMed  Google Scholar 

  24. Flynn TC, Clark RE (2003) 2nd Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 29(5): 519–522

    Article  PubMed  Google Scholar 

  25. Baumann L et al (2003) A double-blinded randomized placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow’s feet: a double-blinded placebo-controlled trial. Dermatol Surg 29(5): 508–515

    PubMed  Google Scholar 

  26. Matarasso SL (2003) Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 29(1): 7–13

    Article  PubMed  Google Scholar 

  27. Borodic G (1998) Myasthenic crisis after botulinum toxin Lancet 352(9143): 1832

    Article  PubMed  CAS  Google Scholar 

  28. Erbguth F et al (1993) Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome J Neurol Neurosurg Psychiatry 56(11): 1235–1236

    PubMed  CAS  Google Scholar 

  29. ATC Draft (2001) Facial aesthetic enhancements: chemodenervation and tissue augmentation pp 76

    Google Scholar 

  30. Finn JC (2004) Botulinum toxin type A: fine-tuning treatment of facial nerve injury. J Drugs Dermatol 3(2): 133–137

    PubMed  Google Scholar 

  31. Flynn TC, Carruthers, JA (2001) Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 27(8): 703–708

    Article  PubMed  CAS  Google Scholar 

  32. Carruthers J, Carruthers A (2001) BOTOX use in the mid and lower face and neck. Semin Cutan Med Surg 20(2): 85–92

    PubMed  CAS  Google Scholar 

  33. Becker-Wegerich PM, Rauch L, Ruzicka T (2002) Botulinum toxin A: successful décolleté rejuvenation. Dermatol Surg 28(2): 168–171

    Article  PubMed  Google Scholar 

  34. Scott AB, Suzuki D (1988) Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3(4): 333–335

    CAS  Google Scholar 

  35. Lange DJ et al (1991) Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes. Muscle Nerve 14(7): 672–675

    Article  PubMed  CAS  Google Scholar 

  36. Girlanda P et al (1992) Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 55(9): 844–845

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2311 M Street, NW Suite 504, Washington, D.C., 20037, USA

    Cheryl M. Burgess M.D., F.A.A.D.

Authors
  1. Cheryl M. Burgess M.D., F.A.A.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. 2311 M Street NW Suite 504, Washington, D.C., 20037, USA

    Cheryl M. Burgess M.D., F.A.A.D.

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Burgess, C.M. (2005). Botulinum Toxin. In: Burgess, C.M. (eds) Cosmetic Dermatology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-27333-6_5

Download citation

  • DOI: https://doi.org/10.1007/3-540-27333-6_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-23064-9

  • Online ISBN: 978-3-540-27333-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation